ArticleBMC infectious diseases2025
Nocardia Nova bacteremia and viral pneumonia in a breast cancer patient post modified radical mastectomy: a case report.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNocardia nova (N. nova) is a Gram-positive aerobic actinomycete and a rare pathogen that can cause severe infections, particularly in immunocompromised patients. CASE PRESENTATION: We report here a rare case of N. nova bacteremia combined with viral pneumonia in a 54-year-old woman who underwent a modified radical mastectomy for breast cancer. Post-surgery, she developed high fever and lung inflammation. Initial empirical therapy with levofloxacin was administered for the pulmonary infection. Upon identification of N. nova through blood cultures and antibiotic susceptibility testing (AST), treatment was switched to trimethoprim-sulfamethoxazole (TMP-SMX) and imipenem/cilastatin, which led to initial improvement. However, the patient relapsed and required an additional six months of antibiotics to achieve full recovery.
conclusionsEstablishing a diagnosis of nocardiosis is a precondition for successful antibiotic therapy. Nocardia bacteremia is a rare event, but it can be confirmed through blood cultures. Our report underscores the pathogenic potential of Nocardia species in patients with underlying conditions, highlighting the critical importance of prompt diagnosis and targeted treatment, especially in postoperative cancer patients at risk for co-infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.